Kallyope Inc.
Elismetrep
Migraine
Countdown
236days
Phase 3 readout · ~ Feb 28, 2027 estimated
What's at stake
Phase 3 trial results for Elismetrep in Migraine are due ~ Feb 28, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT07645924: Phase 3 trial, sponsor Kallyope Inc., drug Elismetrep. Primary completion date 2027-02 (estimated).”